Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%

Dogwood Therapeutics, Inc.

2024-Q1 EPS reported -$0.07

Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.
R&D expenses $0.3M (down from $0.5M); G&A expenses $1.0M (down from $1.1M).
BHC Long-COVID phase 2 trial (IMC-2) exceeded 50% enrollment; top-line data expected H2 2024.
Preliminary safety shows IMC-2 well tolerated; no serious adverse events reported to date.
Global patent for IMC-2 covering Long-COVID and Alzheimer's published; FM partner discussions ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $1.3 million, EPS $0.07 basic and diluted net loss per share.

Period: the first quarter ended March 31, 2024
Net income: $1.3 million
EPS: $0.07 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2024.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.